To the Editor Cardiovascular disease (CVD) remains the leading cause of death in the United States. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an important treatment option for patients at highest risk of CVD who are unable to reach their lipid goals with current treatments. Dr Kazi and colleagues1 suggested that use of PCSK9 inhibitors for patients with atherosclerotic CVD and heterozygous familial hypercholesterolemia is not cost-effective and that these medicines will increase costs to the US health care system. These findings depend on questionable assumptions that overestimate the calculated cost-effectiveness ratio and thus underestimate the value of PCSK9 inhibitors.
Mastey V, Johnstone BM. Cost-effectiveness of PCSK9 Inhibitor Therapy. JAMA. 2016;316(20):2151-2152. doi:10.1001/jama.2016.16286